Inventor
BREHMER DIRK
DE13 patents
⚠️ This page may combine multiple inventors who share the name “BREHMER DIRK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
12 patentsUS11059850B2Jul 13, 2021
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV8 citations81
US10653711B2May 19, 2020
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV6 citations81
US11702441B2Jul 18, 2023
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV2 citations70
US11318157B2May 3, 2022
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV1 citations70
US11883367B2Jan 30, 2024
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations60
US12145961B2Nov 19, 2024
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV0 citations59
US11993614B2May 28, 2024
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations59
US11098062B2Aug 24, 2021
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations59
US11999993B2Jun 4, 2024
Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
JANSSEN PHARMACEUTICA NV0 citations53
US11279970B2Mar 22, 2022
Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
JANSSEN PHARMACEUTICA NV0 citations53
US10898504B2Jan 26, 2021
Substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations47
US11571437B2Feb 7, 2023
Methods of treating cancer using PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations39